AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International ...

head of Alexion’s new development hub, about these new ventures and about why and how big pharma tackles small diseases. Novo’s name change Novo Nordisk is far from new to the world of rare di ...

High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...

The Consumer Healthcare Products Association has elected Sanofi’s Head of North America Consumer Healthcare Andrew Loucks to its Board of Directors. Check out our other roundups for pharma and ...

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty ...

Alexion In December 2024 ... pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareho ...

Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...

Too often, the disconnect between a company’s IT department and its business teams slows progress and leads to missed ...